Approval Year
| Glycosylation Type | MAMMALIAN |
|
|
ACTIVE MOIETY |
The underlying mode of action of this
molecule is to enhance the effector function of tumor-infiltrating T-cells or NK-cells upon
activation by a tumor-targeted T-cell bispecific (TCB) antibody or antibody-dependent cellular cytotoxicity (ADCC), respectively, by crosslinking 4-1BB-positive activated effector cells with CD19+ tumor targets.
|
Showing 1 to 1 of 1 entries